Foundayo Guide
Foundayo (orforglipron) is the first FDA-approved once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management. Approved by the FDA on April 1, 2026, Foundayo is taken as a single tablet once a day with no food or water restrictions, marking a major change from injectable GLP-1s and from oral semaglutide (Rybelsus), which has strict food and water rules. In the 72-week ATTAIN-1 phase 3 trial, the label reports 11.1% mean weight loss on the 17.2 mg dose versus 2.1% on placebo (12.4% versus 0.9% under the trial's efficacy estimand).
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
At a Glance
| Generic Name | Orforglipron |
| Brand Names | Foundayo |
| FDA Status | FDA-approved for chronic weight management in adults with obesity, or overweight with weight-related medical problems, alongside a reduced-calorie diet and increased physical activity (April 1, 2026). Not approved for pediatric use. Use with another GLP-1 receptor agonist is not recommended.[1] |
| Approval Date | April 1, 2026[1] |
How Foundayo Works
Orforglipron is a non-peptide small molecule that binds and activates the GLP-1 receptor directly. Unlike injectable GLP-1 peptides (semaglutide, tirzepatide) or oral peptide formulations (Rybelsus), orforglipron is a true small organic molecule that survives stomach acid and digestion, eliminating the need for injection or special food restrictions. It produces the same downstream effects as injectable GLP-1 agonists: appetite suppression, slowed gastric emptying, and reduced food reward signaling.[2]
Dosing Schedule
Foundayo uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].
Side Effects
Common: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, swollen belly, fatigue, belching, heartburn, gas, hair loss. Serious: pancreatitis, dehydration leading to kidney problems, gallbladder disease, hypoglycemia (especially with insulin/sulfonylureas), serious allergic reactions, diabetic retinopathy progression in T2D patients, increased aspiration risk during anesthesia. Boxed warning: risk of thyroid C-cell tumors, carried as a GLP-1 class warning; orforglipron itself is not pharmacologically active in rats or mice and did not produce tumors in rodents. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).[1][2]
This is not a complete list. Consult your healthcare provider or prescriber for full safety information. The complete adverse reaction profile is published in the current FDA prescribing information[1].
Clinical Trial Results
ATTAIN-1 (NCT05869903) was a 72-week phase 3 randomized placebo-controlled trial of 3,127 adults with obesity or overweight plus a weight-related comorbidity (no diabetes), conducted across 10 countries. Highest dose produced 12.4% mean body weight reduction (~27 lbs) versus 0.9% on placebo (efficacy estimand). Treatment-regimen estimand: 11.1% (~25 lbs) vs 2.1% placebo. Foundayo also reduced waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure across all doses. ATTAIN-2, in patients with type 2 diabetes, has since been published.[2]
Where to Get Foundayo
These telehealth providers offer access to orforglipron with online consultations and home delivery. Before you book a consult, our guide to getting Foundayo online walks through eligibility, the prescriber visit, and what legitimate pharmacy fulfillment looks like.
Found
Best for: medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help
Editorial score · methodology
Editorial score · methodology
ShedRx
Best for: compounded GLP-1 as an injection, drops or lozenges, with lower rates on 6- and 12-month plans
Editorial score · methodology
Ro
Best for: FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help
Editorial score · methodology
Maximus
Best for: men seeking compounded tirzepatide alongside testosterone optimization
Editorial score · methodology
SkinnyRx
Best for: compounded semaglutide or tirzepatide with the consult and free overnight shipping in one price
Editorial score · methodology
Cost Comparison
Each provider's lowest ongoing monthly cash price for Foundayo, sorted cheapest first (no copays, membership fees or intro offers). Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502[5]. Prices may vary based on dose.
| Provider | From (ongoing) | |
|---|---|---|
| Amazon One Medical | $149/momedication billed separately | Visit |
| Found | $149/mo+ required membership | Visit |
| GoodRx | $149/morises with dose | Visit |
| Healthspan | $149/mo+ required membership | Visit |
| Hers | $149/mo+ required membership | Visit |
| Hims | $149/mo+ required membership | Visit |
| HuHealth | $149/mosee plan details | Visit |
| Imbue Health | $149/mo+ required membership | Visit |
| LillyDirect Foundayo | $149/mo | Visit |
| Médetone | $149/mo+ required membership | Visit |
| PrideRx | $149/mo+ required membership | Visit |
| Ro | $149/mo+ required membership | Visit |
| Sesame Care | $149/mosee plan details | Visit |
| ShedRx | $149/mo+ required membership | Visit |
| Temi | $149/morises with dose | Visit |
| Walgreens Weight Management | $149/momedication billed separately | Visit |
| ZipHealth | $149/mosee plan details | Visit |
| PreventiveMD | $198/mo“starting at” price | Visit |
| Maximus | $200/mostarting dose | Visit |
| Alloy | $248/mostarting dose | Visit |
| Phoenix NP | $248/moper 4 weeks | Visit |
| SkinnyRx | $248/mo“starting at” price | Visit |
| Näky | $424/mo+ added fee | Visit |
| Pallas Health | $499/moper 4 weeks | Visit |
Foundayo Head-to-Head Comparisons
Short-form verdict pages comparing Foundayo to other GLP-1 options with trial-anchored data, FDA-label dosing, and current manufacturer pricing.
See all drug-vs-drug verdicts, or compare every weight loss medication we cover.
Foundayo Patient Questions, Answered
Real patient questions about Foundayo pulled from named subreddits and answered with peer-reviewed trial data.
Foundayo Reference Cards
Scannable cheat sheets for dose schedules, missed-dose rules, and red-flag side effects — every number verified against the DailyMed FDA label.
Ranked PubMed Studies on Foundayo
Curated lists of the highest-impact peer-reviewed studies on Foundayo and related GLP-1 drugs. Every PMID is checked against its PubMed record.
Related Research on Foundayo
Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.
Frequently Asked Questions
Sources & methodology (as of November 2026)
- 1.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 2.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 3.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 4.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 5.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Orforglipron · Drugs and brands
- Wegovy · Drugs and brands
- Zepbound · Drugs and brands
- GLP-1 receptor · Mechanism